Introduction
Until recently, temazepam was available in Australia as a tablet and as a soft gelatin capsule (gelcaps). There is little evidence that there was any clinical reason to prescribe gelcaps instead of tablets. 1 There was evidence of an increase in intentional misuse, abuse, dependency and complications related to the injection of the liquid contents of temazepam gelcaps.
Research evidence
The intravenous misuse of temazepam was first reported in Scotland in 1987. 2 International research has shown that temazepam, flunitrazepam and diazepam are the preferred benzodiazepines among injecting drug users. The practice of injecting benzodiazepines, and in particular the contents of temazepam gelcaps, is potentially very harmful and is a significant health issue for injecting drug users. 3, 4 Studies undertaken in Sydney found that benzodiazepines were commonly injected by people who also injected amphetamines or heroin, with diazepam and temazepam being the most likely to be injected. 5 Another study in Southwest Sydney found 25% of injecting drug users had injected benzodiazepines at some time and that temazepam was the most commonly injected. 6 A study in 2002 in Sydney found that while levels of methadone injection had fallen, there had been no decline in the proportion of injecting drug users injecting benzodiazepines. 7 In the Kings Cross area of Sydney, there were anecdotal reports of an increasing problem with the injection of temazepam gelcaps and its associated harms since the heroin shortage in early 2001. 8 Physical complications associated with the injection of temazepam gelcaps (Table 1) Temazepam is insoluble in water and there is evidence that it directly damages vascular epithelium. This means that both the gelcap and tablet formulations are harmful when injected.
Gelcaps were preferentially injected because injecting drug users felt that they worked better than tablets and the contents were in a readily injectable form. They heated the capsules and then drew the contents up into a syringe. The United Kingdom experience
The UK faced similar problems with the injecting misuse of temazepam gelcaps in the early 1990s. In 1996 after education campaigns failed to adequately control the problem, gelcaps were removed from the National Health Service. Injecting drug users did not switch to injecting other benzodiazepines and the change resulted in an almost total disappearance in the injecting misuse of gelcaps and a consequent significant health benefit.
Changes in Australia
In mid-2002, in response to the concerns over misuse, the Pharmaceutical Benefits Advisory Committee rescheduled 10 mg temazepam gelcaps to require an authority prescription. 
Conclusion
The harmful effects of injecting the contents of temazepam gelcaps led to the withdrawal of this product from the Australian market. Doctors still ought to be vigilant to detect harm associated with the misuse of benzodiazepines and carefully consider the need to prescribe drugs with a risk of dependence, particularly to anyone who could be an injecting drug user or be in contact with injecting drug users.
1. Be aware that 'doctor shoppers' tend to present as 'drop ins'. They will often come at the end of a busy surgery and say, 'I won't take up much of your time Doc', or 'I know you're busy, this won't take long'.
2. Put a notice on the surgery notice board stating that you do not prescribe benzodiazepines (or other drugs of dependence).
3. Explain early in the consultation that you do not prescribe benzodiazepines. Table 1 
